Risk Factors for Ceftriaxone-Associated Pseudolithiasis in Adults

Abstract

Introduction: Ceftriaxone (CTRX) is known to occasionally cause pseudolithiasis. This condition is often observed in children; however, few studies have reported the incidence and risk factors for CTRX-associated pseudolithiasis. Methods: In this single-center retrospective study, we investigated the incidence of and risk factors for CTRX-associated pseudolithiasis in adults. All patients underwent computed tomography to confirm pseudolithiasis before and after CTRX administration. Results: The study included 523 patients. Pseudolithiasis was detected in 89 patients (17%). Data analysis showed that abdominal area-related biliary diseases at the site of infection (odds ratio [OR] 0.19, 95% confidence interval [CI] 0.064–0.53, p = 0.0017), CTRX administration for >3 days (OR 5.0, 95% CI: 2.5–9.9, p < 0.0001), CTRX dose of 2 mg (OR 5.2, 95% CI: 2.8–9.6, p < 0.0001), fasting period >2 days (OR 3.2, 95% CI: 1.6–6.4, p = 0.0010), and estimated glomerular filtration rate <30 mL/min/1.73 m² (OR 3.4, 95% CI: 1.6–7.5, p = 0.0022) were independent factors for pseudolithiasis. Conclusions: CTRX-associated pseudolithiasis may occur in adults and should be considered in the differential diagnosis in patients who develop abdominal pain or liver enzyme elevation after CTRX administration, particularly in patients with chronic kidney disease, in those who are fasting, in and those who receive high-dose CTRX therapy.